STAAR Surgical Co
Change company Symbol lookup
Select an option...
STAA STAAR Surgical Co
PFE Pfizer Inc
AGNC Agnc Investment Corp
AAPL Apple Inc
GRTYA Guaranty Corp
SATS EchoStar Corp
$DJI Dow Jones Industrials
TIKK Tel-Instrument Electronics Corp
TEAM Atlassian Corporation PLC
PAYX Paychex Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It manufactures lenses used in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. As of December 29, 2017, the Company sold its products in over 75 countries, with distribution in the United States, Canada, Japan and Spain.

Postmarket

Last Trade
Delayed
$75.37
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$75.37
Day's Change
0.28 (0.37%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
75.54
Day's Low
72.83
Volume
(Light)
Volume:
223,320

10-day average volume:
471,089
223,320

STAAR Surgical to Report Third Quarter Results on November 4, 2020

7:00 am ET October 21, 2020 (BusinessWire) Print

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended October 2, 2020 on Wednesday, November 4, 2020 after the market close.

STAAR will host a conference call and webcast on Wednesday, November 4 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 6253229), please dial 833-350-1429 for domestic participants and 647-689-6661 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Conference ID 6253229) will be available beginning approximately one hour after the call's conclusion for seven days. This replay can be accessed by dialing 800-585-8367 for domestic callers and 416-621-4642 for international callers. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer(R) Lens or "ICL", which includes the EVO Visian ICL(TM) product line. More than 1,000,000 Visian(R) ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company's website at www.staar.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005200/en/

SOURCE: STAAR Surgical Company

Investors & Media 
Brian Moore
Vice President, Investor, Media Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.